The present study aimed to evaluate the effect of SGLT2 inhibitor dapagliflozin (DAPA) on DCM, especially cardiac fibrosis and EndMT in a rat model of type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.